Holen Sie sich die Stockscreener-App
0.7592
1.36%
0.0102
Handel nachbörslich:
.78
0.0208
+2.74%
Schlusskurs vom Vortag:
$0.749
Offen:
$0.755
24-Stunden-Volumen:
379.40K
Relative Volume:
0.50
Marktkapitalisierung:
$87.63M
Einnahmen:
$3.17M
Nettoeinkommen (Verlust:
$-36.23M
KGV:
-1.8571
EPS:
-0.4088
Netto-Cashflow:
$-17.11M
1W Leistung:
-11.93%
1M Leistung:
-14.79%
6M Leistung:
-33.40%
1J Leistung:
+58.43%
1-Tages-Spanne:
$0.7306
$0.775
1-Wochen-Bereich:
$0.7306
$0.8698
52-Wochen-Spanne:
$0.4453
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Firmenname
Rani Therapeutics Holdings Inc
Sektor
Branche
Telefon
(408) 457-3700
Adresse
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.7592 | 87.63M | 3.17M | -36.23M | -17.11M | -0.4088 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Lake Street | Buy |
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-14 | Eingeleitet | Maxim Group | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-07-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten
Rani Therapeutics (RANI) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
RANI Stock Price, Quote & Chart - ChartMill
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN) - The Globe and Mail
Rani Therapeutics Holdings (RANI) Trades at $0.82, Holding a Narrow Sub-$1 RangeMerger Arbitrage - careplusvn.com
Rani Therapeutics at H.C. Wainwright: oral biologics gain traction By Investing.com - Investing.com UK
RANI: RaniPill's strong clinical data and major partnerships drive growth, with manufacturing and cash runway secured - tradingview.com
Rani Therapeutics (RANI) Institutional Ownership 2026 $RANI - MarketBeat
Rani Therapeutics Holdings, Inc. (RANI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rani Therapeutics will appear in New York on Sept. 10 and 14 - Stock Titan
Rani Therapeutics to Participate in Upcoming September Conferences - GlobeNewswire
Rani Therapeutics Holdings Stock Price Forecast. Should You Buy RANI? - StockInvest.us
Rani Therapeutics Holdings Inc (RANI) Peer Comparison – Compare with Others - valueresearchonline.com
RANI Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pre-Revenue Stage - careplusvn.com
Rani Therapeutics Holdings Inc (RANI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Rani (RANI) Earnings Report: EPS Beats Its Estimate in Latest Trading; Trading Response: The Stock Gains 3.41% on the DayGuidance Accuracy Score - vinanet.vn
Rani (RANI) Trading: Finishes 3.41% Up at $0.88 in the Latest Session; Technical View: the Supplied Trading Band Runs From $0.84 to $0.92 in the Available RecordTWAP Entry - vinanet.vn
HC Wainwright Reaffirms "Buy" Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy - Investing.com
We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely - webull.com
Chardan Capital Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tues - Benzinga
Chardan Capital Initiates Coverage on Rani Therapeutics (NASDAQ:RANI) - MarketBeat
RANI Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Jump 9.5%Dividend Earnings Report - careplusvn.com
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - MarketBeat
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics (RANI) Edges Lower to $0.80 as Stock Tests Crucial Support ZonePercent Below MA - vinanet.vn
RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap - Stock Titan
Rani Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates - Investing.com Canada
8-K: Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Updatemoomoo - Moomoo
Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85% - scanx.trade
Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue - Stock Titan
Rani Therapeutics reports Q2 2026: $1.7M contract revenue, $8.4M quarterly net loss, $53.4M cash - TradingView
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability - Stock Titan
Rani Therapeutics at Canaccord Genuity conference: oral biologics push By Investing.com - Investing.com Canada
RANI: Oral biologics platform shows strong clinical and business momentum, with funding secured into 2027 - TradingView
Rani Therapeutics (RANI) Edges Higher by 2.93% as Shares Approach Key $0.84 ResistanceVolume Oscillator - careplusvn.com
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Rani Therapeutics CEO, CFO to Present, Hold 1x1 Meetings Aug. 12 - Stock Titan
Rani Therapeutics Holdings Inc (RANI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RANI Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Rani Therapeutics appoints Michelle Gilson to board - The Globe and Mail
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director - Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) details director option holding - Stock Titan
Rani Therapeutics files Form 3 for director Michelle Gilson - Bitget
Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair - Quiver Quantitative
Finanzdaten der Rani Therapeutics Holdings Inc-Aktie (RANI)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):